Stock market - shares to follow in Paris and Europe (updated) - 01/17/2022 at 08:39

Followed by shares tomorrow on the Paris Stock Exchange Thursday, January 20, 2022 – 01/19/2022 at 6:25 pm

(AOF) –

AB Science

AB Science has announced that it has received clearance from ANSM to begin a Phase II study (AB20006) in patients with severe mast cell activation syndrome. The study will recruit 60 patients across multiple centers. The goal of treatment in severe MCAS is to reduce symptoms (itching, redness, depression) and to improve patients’ poor quality of life. The AB20006 study was also approved in the United States by the Food and Drug Administration (FDA).

Alstom

The railroad specialist (pre-market) will publish its turnover for the third quarter.

Axway Software

If Axway is able to confirm its 2021 profitability target that provides an operating margin of activity that is at least 11% of its turnover, the company announces that the latter will not see the expected organic growth. While the company had expected organic revenue growth of between 2% and 4% in 2021, preliminary estimates, at this point, not final and unaudited, show annual revenue of around €285.5 million, an organic decline of about 2.7%.

Boiron

The homeopathic (after-market) specialist will publish its annual sales.

Commonwealth of Independent States

The Rules of Living in Hostile Environments specialist will publish its annual turnover.

Alpine company

The ski and theme park operator (after the market) will publish its sales volume for the first quarter.

take link

The Channel Tunnel franchisee will publish its annual sales.

Pierre and Holidays

The holiday villages and holiday homes specialist will publish (after market) its sales for the first quarter.

phycoenol

The animal health professional will publish their annual sales figure.

Valniva

Valneva announces results of a preliminary lab study showing that antibodies from the serum of people vaccinated with three doses of the inactivated candidate Covid-19 vaccine, VLA2001, neutralize the alternative Omicron. Serum from 30 participants in the Phase 1/2 trial, VLA2001-201, was used in a virus-like assay to assess neutralization of the historical SARS-CoV-2 virus as well as delta and omicron virus.

Vinci

HEB Construction, a subsidiary of New Zealand’s Vinci Construction, will work in alliance with Fulton Hogan to design and build Takitimu North Link, southeast Auckland. The business, valued at NZ$655 million (€391 million), will last about five years. It covers the construction of a new 2×2 road, as well as a 6.8 km bike and pedestrian lane. This project includes the construction of eight bridges, 29 canals and eight diversions of the watercourse.

Verpac

Virbac lifted the veil on its annual turnover for 2021: 1.06 billion euros, compared to 934.2 million a year earlier, a total increase of 17.4% excluding Sentinel (+13.9% in effective range) compared to 2020. Excluding the unfavorable impact of exchange rates, it rose Revenue at 18.4% excluding Sentinel (+14.9% in effective range). All areas were reported in double digit organic growth throughout the year, reflecting the dynamics of the sector and the very good implementation of the strategic plan, welcoming the animal health specialist.

.

Leave a Comment

Your email address will not be published.